[{"id":"f63a7e1f-3ff4-4374-bcb2-6ae04e50efbd","acronym":"PRO-R-IPI","url":"https://clinicaltrials.gov/study/NCT01369784","created_at":"2021-01-18T05:36:38.960Z","updated_at":"2024-07-02T16:37:32.697Z","phase":"","brief_title":"Prognostic Value of Clinical and Biological Factors in Patients With Refractory/Relapsed Diffuse Large B-cell Lymphoma","source_id_and_acronym":"NCT01369784 - PRO-R-IPI","lead_sponsor":"Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea","biomarkers":" TP53 • BCL2 • BCL6 • IRF4 • LXN","pipe":" | ","alterations":" BCL2 expression • TP53 expression • IRF4 expression","tags":["TP53 • BCL2 • BCL6 • IRF4 • LXN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL2 expression • TP53 expression • IRF4 expression"],"overall_status":"Completed","enrollment":" Enrollment 158","initiation":"Initiation: 02/01/2009","start_date":" 02/01/2009","primary_txt":" Primary completion: 03/01/2011","primary_completion_date":" 03/01/2011","study_txt":" Completion: 03/01/2011","study_completion_date":" 03/01/2011","last_update_posted":"2016-04-18"}]